Evidence map›Paper›PMID 34643914›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Drug Efficacy Testing in the Mouse Footpad Model of Buruli Ulcer.

Paul J Converse, Deepak V Almeida, Eric L Nuermberger

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Paul J Converse *Center for TB Research, Johns Hopkins University, Baltimore, MD, USA. pconver1@jhmi.edu.
Deepak V Almeida *Center for TB Research, Johns Hopkins University, Baltimore, MD, USA.
Eric L NuermbergerCenter for TB Research, Johns Hopkins University, Baltimore, MD, USA.
Johns Hopkins University · US

Funding

Closing the Gaps on Buruli Ulcer Diagnosis, Treatment, and PreventionR01AI113266 · NIAID · JOHNS HOPKINS UNIVERSITY · PI NUERMBERGER, ERIC L · 2016 to 2020
$4.4M
Firing up new treatments against Mycobacterium ulcerans disease (Buruli ulcer)R01AI082612 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GROSSET, JACQUES H. · 2009 to 2013
$2.0M
NIAID NIH HHS R01 AI082612NIAID NIH HHS R01 AI113266
6 · The paper itself

Abstract

Great progress has been made in understanding the pathogenesis and treatment of Buruli ulcer over the last 20 years. The rediscovery of the mouse footpad model of the disease with translation to clinical practice has changed treatment of this infectious disease, caused by Mycobacterium ulcerans, from surgery and skin grafting to the administration of antibiotics for 8 weeks or less with superior cure rates. Here we describe the development and enhancement of the mouse model during the last two decades.

Indexed as

Buruli UlcerMycobacterium ulceransAnimalsAnti-Bacterial AgentsDisease Models, AnimalMicePharmaceutical PreparationsAnti-Bacterial AgentsPharmaceutical PreparationsBuruli ulcerMycobacterium ulcerans

Identifiers

PMID34643914
PMCPMC8996816
OpenAlexW3205407691

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.